More recently described biomarkers are considered either intermediate risk (with 30–70% risk for cancer, such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic [AMPA]-receptor [R] antibody) or low risk (with 30% cancer risk, such as glial fibrillary acidic protein [GFAP]-IgG) [3, 4•]. The gene discussed is GFAP; the disease is cancer.